September 2019

JDRF's Kowalski Sees Hope in Bipartisan Support for Insulin Pricing Reform

September 26, 2019

Evidence-Based Diabetes Management

Aaron Kowalski, PhD, the new CEO of the JDRF, says in a discussion about insulin pricing that action is needed not only by Congress, but also by insulin makers, health plans, and the executive branch. The most important goal: ending a crosspayment scheme that many blame for potentially deadly price increases.

Gathering Evidence on Insulin Rationing: Answers and Future Questions

September 26, 2019

Evidence-Based Diabetes Management

The results of a study published last year from authors at Yale Diabetes Center suggest that rationing is more common than the healthcare system wants to admit. Senior author Kasia Lipska, MD, MHS, says the findings raise a whole new set of questions.

For Young Adults With Type 1 Diabetes, Insulin Costs Can Mean Chasing Benefits, Not Dreams

September 25, 2019

Evidence-Based Diabetes Management

“Diabetes fully ripped my life and potential away. I always grew up thinking I would be a professional musician. I feel like I’m still mourning the loss of what my life would have been.” --Sarah Tackett, age 26

As a Child, Diabetes Was Hard to Accept. Now She's Living With the Complications

September 25, 2019

Evidence-Based Diabetes Management

The diagnosis of diabetes can be hard for a teenager to accept. Add insulin affordability to the mix, and by the time a young adult learns to live with the disease, the complications have already arrived.

How Prepared Is the United States for the Transition of Insulins to Regulation as Biologics?

September 27, 2019

Evidence-Based Diabetes Management

From The Center for Biosimilars®, a discussion of a regulatory change coming in 2020: Insulins have always been biologics from a scientific perspective, and the products themselves will not change as a result of bringing them under regulation as biologics as a matter of law. However, labeling for these products will change.

Impact of Switching Analogue Insulin to Human Insulin in Diabetes

September 27, 2019

Evidence-Based Diabetes Management

Converting from analogue insulin to human insulin is associated with a clinical insignificant increase in glycated hemoglobin of 0.16% but with improved insulin adherence.

Examining the Reality of What Insulin Costs Do to Patients

September 27, 2019

Evidence-Based Diabetes Management

The editor-in-chief of Evidence-Based Diabetes Management™ introduces the special issue, Perspectives on Insulin Pricing, and shares that he has seen rationing among his own patients.